| Ytd | -22.64% | |
| 1y | 75.04% |
| Open | 12.57 | Prev Close | 12.60 | Low | 12.02 | High | 12.64 | Mkt Cap | 1.03B |
| Vol | 1.60M | Avg Vol | 1.44M | EPS | -1.75 | P/E | N/A | Forward P/E | -6.47 |
| Beta | 1.50 | Short Ratio | 12.28 | Inst. Own | 116.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 17.38 | 200-d Avg | 18.47 | 1yr Est | 28.50 |
GLUE News
Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperfor
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under
Monte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and mil
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-
Bank of America Corp DE lifted its stake in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) by 73.3% du
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy an
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free sur
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutat
Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight a
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweig
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Co
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed th
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascu
Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a ye
Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valua
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Co
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP re
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a wei
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vi
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendat
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after pos
On Monday, 369 companies set new 52-week lows.
On Wednesday, 345 companies set new 52-week lows.
Tuesday's session saw 286 companies set new 52-week lows.
On Monday, 147 stocks made new 52-week lows.
On Friday, 497 companies set new 52-week lows.
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announc